ZA200500614B - Improved treatment of cancer with glutamine - Google Patents

Info

Publication number

ZA200500614B

ZA200500614B ZA200500614A ZA200500614A ZA200500614B ZA 200500614 B ZA200500614 B ZA 200500614B ZA 200500614 A ZA200500614 A ZA 200500614A ZA 200500614 A ZA200500614 A ZA 200500614A ZA 200500614 B ZA200500614 B ZA 200500614B

Authority

ZA

South Africa

Prior art keywords

glutamine

composition

subject

tissue

carbohydrate

Prior art date

2002-08-01

Links

• Espacenet
• Global Dossier
• Discuss

• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims description 513
• 206010028980 Neoplasm Diseases 0.000 title claims description 154
• 201000011510 cancer Diseases 0.000 title claims description 74
• 238000011282 treatment Methods 0.000 title description 35
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 251
• 239000000203 mixture Substances 0.000 claims description 190
• 150000001720 carbohydrates Chemical class 0.000 claims description 147
• 235000014633 carbohydrates Nutrition 0.000 claims description 145
• 229960003180 glutathione Drugs 0.000 claims description 125
• 210000001519 tissue Anatomy 0.000 claims description 110
• 210000004027 cell Anatomy 0.000 claims description 96
• 230000000694 effects Effects 0.000 claims description 94
• 238000010521 absorption reaction Methods 0.000 claims description 88
• 239000003814 drug Substances 0.000 claims description 87
• 150000001413 amino acids Chemical class 0.000 claims description 82
• 150000003839 salts Chemical class 0.000 claims description 69
• 230000001965 increasing effect Effects 0.000 claims description 63
• 238000002512 chemotherapy Methods 0.000 claims description 58
• 238000001959 radiotherapy Methods 0.000 claims description 45
• 238000002360 preparation method Methods 0.000 claims description 39
• 208000027418 Wounds and injury Diseases 0.000 claims description 38
• 210000000481 breast Anatomy 0.000 claims description 36
• 108010024636 Glutathione Proteins 0.000 claims description 34
• 230000007423 decrease Effects 0.000 claims description 31
• 230000006378 damage Effects 0.000 claims description 29
• 208000026310 Breast neoplasm Diseases 0.000 claims description 26
• 210000004400 mucous membrane Anatomy 0.000 claims description 26
• 206010052428 Wound Diseases 0.000 claims description 24
• 206010006187 Breast cancer Diseases 0.000 claims description 23
• 210000000981 epithelium Anatomy 0.000 claims description 21
• 210000000822 natural killer cell Anatomy 0.000 claims description 19
• 230000006907 apoptotic process Effects 0.000 claims description 18
• 208000014674 injury Diseases 0.000 claims description 18
• 230000005855 radiation Effects 0.000 claims description 17
• 208000015181 infectious disease Diseases 0.000 claims description 15
• 230000003902 lesion Effects 0.000 claims description 14
• 150000002016 disaccharides Chemical class 0.000 claims description 13
• 230000001737 promoting effect Effects 0.000 claims description 12
• 230000009467 reduction Effects 0.000 claims description 12
• 208000002193 Pain Diseases 0.000 claims description 11
• 230000002708 enhancing effect Effects 0.000 claims description 11
• 150000002772 monosaccharides Chemical class 0.000 claims description 11
• 239000007864 aqueous solution Substances 0.000 claims description 10
• 230000035876 healing Effects 0.000 claims description 10
• 150000005846 sugar alcohols Chemical class 0.000 claims description 10
• 206010030113 Oedema Diseases 0.000 claims description 8
• 208000025865 Ulcer Diseases 0.000 claims description 8
• 239000002246 antineoplastic agent Substances 0.000 claims description 6
• 229940127089 cytotoxic agent Drugs 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• 208000006877 Insect Bites and Stings Diseases 0.000 claims description 5
• 230000001580 bacterial effect Effects 0.000 claims description 5
• 230000002147 killing effect Effects 0.000 claims description 5
• 231100001274 therapeutic index Toxicity 0.000 claims description 5
• 206010027476 Metastases Diseases 0.000 claims description 4
• 208000036142 Viral infection Diseases 0.000 claims description 4
• 230000008030 elimination Effects 0.000 claims description 4
• 238000003379 elimination reaction Methods 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• 231100000397 ulcer Toxicity 0.000 claims description 4
• 230000009385 viral infection Effects 0.000 claims description 4
• 238000005299 abrasion Methods 0.000 claims description 3
• 238000011319 anticancer therapy Methods 0.000 claims description 3
• 239000003125 aqueous solvent Substances 0.000 claims description 3
• 239000003124 biologic agent Substances 0.000 claims description 3
• 208000035143 Bacterial infection Diseases 0.000 claims description 2
• 206010011985 Decubitus ulcer Diseases 0.000 claims description 2
• 206010017533 Fungal infection Diseases 0.000 claims description 2
• 208000034693 Laceration Diseases 0.000 claims description 2
• 208000031888 Mycoses Diseases 0.000 claims description 2
• 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
• 230000002538 fungal effect Effects 0.000 claims description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 291
• 229960002743 glutamine Drugs 0.000 description 280
• 235000004554 glutamine Nutrition 0.000 description 244
• 238000000034 method Methods 0.000 description 125
• ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 104
• VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 84
• 229940024606 amino acid Drugs 0.000 description 80
• 235000001014 amino acid Nutrition 0.000 description 80
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
• 230000009469 supplementation Effects 0.000 description 62
• 241000700159 Rattus Species 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 48
• 102000004169 proteins and genes Human genes 0.000 description 45
• 230000014509 gene expression Effects 0.000 description 44
• 239000003981 vehicle Substances 0.000 description 40
• 235000018102 proteins Nutrition 0.000 description 39
• 229930182816 L-glutamine Natural products 0.000 description 37
• 241001465754 Metazoa Species 0.000 description 34
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 31
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 31
• 230000035699 permeability Effects 0.000 description 29
• 239000000243 solution Substances 0.000 description 29
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 28
• 108090000397 Caspase 3 Proteins 0.000 description 23
• 102000003952 Caspase 3 Human genes 0.000 description 23
• 239000007788 liquid Substances 0.000 description 23
• 210000003491 skin Anatomy 0.000 description 23
• -1 glutamine Chemical class 0.000 description 22
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 21
• 229930006000 Sucrose Natural products 0.000 description 21
• 230000004700 cellular uptake Effects 0.000 description 21
• 239000012528 membrane Substances 0.000 description 21
• 239000005720 sucrose Substances 0.000 description 21
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 20
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 20
• 235000010356 sorbitol Nutrition 0.000 description 20
• 239000000600 sorbitol Substances 0.000 description 20
• 229960002920 sorbitol Drugs 0.000 description 20
• 230000001225 therapeutic effect Effects 0.000 description 20
• 102000004190 Enzymes Human genes 0.000 description 19
• 108090000790 Enzymes Proteins 0.000 description 19
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
• 108091008611 Protein Kinase B Proteins 0.000 description 19
• 230000003247 decreasing effect Effects 0.000 description 19
• 210000001035 gastrointestinal tract Anatomy 0.000 description 19
• 210000004379 membrane Anatomy 0.000 description 19
• 239000003921 oil Substances 0.000 description 19
• 235000019198 oils Nutrition 0.000 description 19
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 17
• 230000015572 biosynthetic process Effects 0.000 description 17
• 239000000872 buffer Substances 0.000 description 17
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
• 238000004519 manufacturing process Methods 0.000 description 17
• 239000007787 solid Substances 0.000 description 17
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 16
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 16
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 16
• 210000002919 epithelial cell Anatomy 0.000 description 16
• 239000000499 gel Substances 0.000 description 16
• 239000000594 mannitol Substances 0.000 description 16
• 230000032258 transport Effects 0.000 description 16
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 15
• 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 15
• 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 15
• 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 15
• 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 15
• 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 15
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 15
• 229960001230 asparagine Drugs 0.000 description 15
• 150000001875 compounds Chemical class 0.000 description 15
• 235000005911 diet Nutrition 0.000 description 15
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 15
• 239000000811 xylitol Substances 0.000 description 15
• 235000010447 xylitol Nutrition 0.000 description 15
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 15
• 229960002675 xylitol Drugs 0.000 description 15
• 238000009472 formulation Methods 0.000 description 14
• 235000000346 sugar Nutrition 0.000 description 14
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
• 108010053070 Glutathione Disulfide Proteins 0.000 description 13
• 229930195725 Mannitol Natural products 0.000 description 13
• 239000013543 active substance Substances 0.000 description 13
• 108700000707 bcl-2-Associated X Proteins 0.000 description 13
• 102000055102 bcl-2-Associated X Human genes 0.000 description 13
• 239000002775 capsule Substances 0.000 description 13
• 230000002496 gastric effect Effects 0.000 description 13
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 13
• 108010004620 glycylsarcosine Proteins 0.000 description 13
• VYAMLSCELQQRAE-UHFFFAOYSA-N glycylsarcosine zwitterion Chemical compound OC(=O)CN(C)C(=O)CN VYAMLSCELQQRAE-UHFFFAOYSA-N 0.000 description 13
• 235000010355 mannitol Nutrition 0.000 description 13
• 239000008159 sesame oil Substances 0.000 description 13
• 235000011803 sesame oil Nutrition 0.000 description 13
• 238000003786 synthesis reaction Methods 0.000 description 13
• 229960004150 aciclovir Drugs 0.000 description 12
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 12
• 208000035475 disorder Diseases 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• 230000003834 intracellular effect Effects 0.000 description 12
• 239000012047 saturated solution Substances 0.000 description 12
• 239000003826 tablet Substances 0.000 description 12
• 230000004614 tumor growth Effects 0.000 description 12
• 241000124008 Mammalia Species 0.000 description 11
• 239000000969 carrier Substances 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 230000000968 intestinal effect Effects 0.000 description 11
• 208000008953 Cryptosporidiosis Diseases 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 230000008901 benefit Effects 0.000 description 10
• 238000003304 gavage Methods 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 239000006228 supernatant Substances 0.000 description 10
• 208000005623 Carcinogenesis Diseases 0.000 description 9
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 9
• 239000012981 Hank's balanced salt solution Substances 0.000 description 9
• 208000019155 Radiation injury Diseases 0.000 description 9
• 239000012867 bioactive agent Substances 0.000 description 9
• 230000036952 cancer formation Effects 0.000 description 9
• 239000007894 caplet Substances 0.000 description 9
• 231100000504 carcinogenesis Toxicity 0.000 description 9
• 229940112822 chewing gum Drugs 0.000 description 9
• 235000015218 chewing gum Nutrition 0.000 description 9
• 230000000378 dietary effect Effects 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 229940068196 placebo Drugs 0.000 description 9
• 239000000902 placebo Substances 0.000 description 9
• 229920005862 polyol Polymers 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 239000007983 Tris buffer Substances 0.000 description 8
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 8
• 235000011187 glycerol Nutrition 0.000 description 8
• 235000019534 high fructose corn syrup Nutrition 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 210000000936 intestine Anatomy 0.000 description 8
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
• 210000000214 mouth Anatomy 0.000 description 8
• 150000003077 polyols Chemical class 0.000 description 8
• 239000003755 preservative agent Substances 0.000 description 8
• 239000000829 suppository Substances 0.000 description 8
• 239000006188 syrup Substances 0.000 description 8
• 235000020357 syrup Nutrition 0.000 description 8
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
• 230000005748 tumor development Effects 0.000 description 8
• 230000003827 upregulation Effects 0.000 description 8
• 206010011502 Cryptosporidiosis infection Diseases 0.000 description 7
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 7
• 235000003704 aspartic acid Nutrition 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 235000009508 confectionery Nutrition 0.000 description 7
• 239000012530 fluid Substances 0.000 description 7
• 235000013350 formula milk Nutrition 0.000 description 7
• 239000004615 ingredient Substances 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 150000003384 small molecules Chemical class 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 239000003381 stabilizer Substances 0.000 description 7
• 210000004881 tumor cell Anatomy 0.000 description 7
• 102000051485 Bcl-2 family Human genes 0.000 description 6
• 108700038897 Bcl-2 family Proteins 0.000 description 6
• 241000792859 Enema Species 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 206010028116 Mucosal inflammation Diseases 0.000 description 6
• 201000010927 Mucositis Diseases 0.000 description 6
• 240000008042 Zea mays Species 0.000 description 6
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
• 238000002835 absorbance Methods 0.000 description 6
• 230000009286 beneficial effect Effects 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 210000001185 bone marrow Anatomy 0.000 description 6
• 239000000679 carrageenan Substances 0.000 description 6
• 229920001525 carrageenan Polymers 0.000 description 6
• 229940113118 carrageenan Drugs 0.000 description 6
• 235000005822 corn Nutrition 0.000 description 6
• 231100000135 cytotoxicity Toxicity 0.000 description 6
• 230000003013 cytotoxicity Effects 0.000 description 6
• 230000037213 diet Effects 0.000 description 6
• 239000006185 dispersion Substances 0.000 description 6
• 239000007920 enema Substances 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 230000002294 pubertal effect Effects 0.000 description 6
• 239000006104 solid solution Substances 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 206010012735 Diarrhoea Diseases 0.000 description 5
• 206010049416 Short-bowel syndrome Diseases 0.000 description 5
• 230000001640 apoptogenic effect Effects 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 235000010418 carrageenan Nutrition 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 238000000502 dialysis Methods 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 229940095399 enema Drugs 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 230000004907 flux Effects 0.000 description 5
• 239000003349 gelling agent Substances 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 210000004347 intestinal mucosa Anatomy 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 210000005075 mammary gland Anatomy 0.000 description 5
• 235000016709 nutrition Nutrition 0.000 description 5
• 238000011275 oncology therapy Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 239000002562 thickening agent Substances 0.000 description 5
• 230000029663 wound healing Effects 0.000 description 5
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 241000223936 Cryptosporidium parvum Species 0.000 description 4
• MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 4
• 150000008540 L-glutamines Chemical class 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• 108091007960 PI3Ks Proteins 0.000 description 4
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
• 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 4
• 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 4
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 230000000844 anti-bacterial effect Effects 0.000 description 4
• 108010007734 bcl-Associated Death Protein Proteins 0.000 description 4
• 102000007348 bcl-Associated Death Protein Human genes 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 201000008275 breast carcinoma Diseases 0.000 description 4
• 238000004364 calculation method Methods 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 210000000172 cytosol Anatomy 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
• 229960002216 methylparaben Drugs 0.000 description 4
• 229940051866 mouthwash Drugs 0.000 description 4
• 230000035764 nutrition Effects 0.000 description 4
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000004962 physiological condition Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000000861 pro-apoptotic effect Effects 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 238000002731 protein assay Methods 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 229940083037 simethicone Drugs 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 238000013223 sprague-dawley female rat Methods 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 208000003265 stomatitis Diseases 0.000 description 4
• 229940034610 toothpaste Drugs 0.000 description 4
• 239000000606 toothpaste Substances 0.000 description 4
• 238000011200 topical administration Methods 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 229920001285 xanthan gum Polymers 0.000 description 4
• 239000000230 xanthan gum Substances 0.000 description 4
• 235000010493 xanthan gum Nutrition 0.000 description 4
• 229940082509 xanthan gum Drugs 0.000 description 4
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
• AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 230000007730 Akt signaling Effects 0.000 description 3
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 3
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 3
• 102100030497 Cytochrome c Human genes 0.000 description 3
• 108010075031 Cytochromes c Proteins 0.000 description 3
• 229930195711 D-Serine Natural products 0.000 description 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
• 108020005124 DNA Adducts Proteins 0.000 description 3
• 239000004375 Dextrin Substances 0.000 description 3
• 229920001353 Dextrin Polymers 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 206010030201 Oesophageal ulcer Diseases 0.000 description 3
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000002424 anti-apoptotic effect Effects 0.000 description 3
• 239000008135 aqueous vehicle Substances 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 230000037444 atrophy Effects 0.000 description 3
• 239000013553 cell monolayer Substances 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 229920002301 cellulose acetate Polymers 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 239000008367 deionised water Substances 0.000 description 3
• 229910021641 deionized water Inorganic materials 0.000 description 3
• 230000000994 depressogenic effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 235000019425 dextrin Nutrition 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 208000028299 esophageal disease Diseases 0.000 description 3
• 208000019064 esophageal ulcer Diseases 0.000 description 3
• 210000003238 esophagus Anatomy 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• 150000002308 glutamine derivatives Chemical class 0.000 description 3
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
• 210000005205 gut mucosa Anatomy 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000006882 induction of apoptosis Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 208000018773 low birth weight Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 210000003470 mitochondria Anatomy 0.000 description 3
• 230000002438 mitochondrial effect Effects 0.000 description 3
• 239000002324 mouth wash Substances 0.000 description 3
• 210000004877 mucosa Anatomy 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000004302 potassium sorbate Substances 0.000 description 3
• 235000010241 potassium sorbate Nutrition 0.000 description 3
• 229940069338 potassium sorbate Drugs 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 210000000664 rectum Anatomy 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
• 238000012453 sprague-dawley rat model Methods 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 230000000153 supplemental effect Effects 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000007723 transport mechanism Effects 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
• 108020004463 18S ribosomal RNA Proteins 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 235000019885 Avicel® cellulose gel Nutrition 0.000 description 2
• 208000022526 Canavan disease Diseases 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 2
• WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 2
• YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 2
• MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
• ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 2
• ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
• YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 2
• ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 108010016626 Dipeptides Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010073306 Exposure to radiation Diseases 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 229920002774 Maltodextrin Polymers 0.000 description 2
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• SLFHWLMXLIRLPS-DFWYDOINSA-N N[C@@H](CCC(N)=O)C(=O)O.[Na] Chemical compound N[C@@H](CCC(N)=O)C(=O)O.[Na] SLFHWLMXLIRLPS-DFWYDOINSA-N 0.000 description 2
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
• 208000007117 Oral Ulcer Diseases 0.000 description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
• 238000009004 PCR Kit Methods 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 229920000153 Povidone-iodine Polymers 0.000 description 2
• 238000010240 RT-PCR analysis Methods 0.000 description 2
• 208000007107 Stomach Ulcer Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 206010042496 Sunburn Diseases 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 235000005550 amino acid supplement Nutrition 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 229940089687 anhydrous monobasic sodium phosphate Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 230000034720 apoptotic signaling pathway Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
• 238000009739 binding Methods 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000003139 buffering effect Effects 0.000 description 2
• 230000009702 cancer cell proliferation Effects 0.000 description 2
• 230000000711 cancerogenic effect Effects 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 231100000315 carcinogenic Toxicity 0.000 description 2
• 230000001013 cariogenic effect Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 229960002173 citrulline Drugs 0.000 description 2
• 235000013477 citrulline Nutrition 0.000 description 2
• 230000000112 colonic effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000002537 cosmetic Substances 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 238000000326 densiometry Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 210000003722 extracellular fluid Anatomy 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000003889 eye drop Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 230000009969 flowable effect Effects 0.000 description 2
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 125000002642 gamma-glutamyl group Chemical group 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
• 235000012907 honey Nutrition 0.000 description 2
• 229960002591 hydroxyproline Drugs 0.000 description 2
• 235000015243 ice cream Nutrition 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 235000011475 lollipops Nutrition 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 231100000533 low birth weight Toxicity 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• 230000001071 malnutrition Effects 0.000 description 2
• 235000000824 malnutrition Nutrition 0.000 description 2
• 235000010449 maltitol Nutrition 0.000 description 2
• 239000000845 maltitol Substances 0.000 description 2
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
• 229940035436 maltitol Drugs 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 230000019735 mitochondria-nucleus signaling pathway Effects 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 230000036651 mood Effects 0.000 description 2
• 239000004081 narcotic agent Substances 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 229960003104 ornithine Drugs 0.000 description 2
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 230000006659 positive regulation of apoptotic process Effects 0.000 description 2
• 229960001621 povidone-iodine Drugs 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 239000012266 salt solution Substances 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 238000007790 scraping Methods 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
• QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
• OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
• KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
• KZZWQCKYLNIOBT-UHFFFAOYSA-N 5-amino-2-nitrobenzoic acid Chemical compound NC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 KZZWQCKYLNIOBT-UHFFFAOYSA-N 0.000 description 1
• LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
• 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102000034263 Amino acid transporters Human genes 0.000 description 1
• 108050005273 Amino acid transporters Proteins 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010070545 Bacterial translocation Diseases 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 206010007269 Carcinogenicity Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
• 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 206010011499 Cryptosporidia infections Diseases 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
• LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-RSVSWTKNSA-N D-altro-hexose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-RSVSWTKNSA-N 0.000 description 1
• UQPHVQVXLPRNCX-GSVOUGTGSA-N D-erythrulose Chemical compound OC[C@@H](O)C(=O)CO UQPHVQVXLPRNCX-GSVOUGTGSA-N 0.000 description 1
• BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• LKDRXBCSQODPBY-IANNHFEVSA-N D-sorbose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-IANNHFEVSA-N 0.000 description 1
• LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
• 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 1
• 229920005682 EO-PO block copolymer Polymers 0.000 description 1
• 208000032163 Emerging Communicable disease Diseases 0.000 description 1
• 239000004386 Erythritol Substances 0.000 description 1
• UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
• 206010056474 Erythrosis Diseases 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 102000054184 GADD45 Human genes 0.000 description 1
• 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
• 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 229920002148 Gellan gum Polymers 0.000 description 1
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
• 108010063907 Glutathione Reductase Proteins 0.000 description 1
• 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
• 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 108010008488 Glycylglycine Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 206010021531 Impetigo Diseases 0.000 description 1
• 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 206010022714 Intestinal ulcer Diseases 0.000 description 1
• 101710172804 K protein Proteins 0.000 description 1
• LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 206010023644 Lacrimation increased Diseases 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102100032241 Lactotransferrin Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025282 Lymphoedema Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 206010028034 Mouth ulceration Diseases 0.000 description 1
• 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 108090000279 Peptidyltransferases Proteins 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 238000011530 RNeasy Mini Kit Methods 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101100437310 Rattus norvegicus Bax gene Proteins 0.000 description 1
• 101100381518 Rattus norvegicus Bcl2 gene Proteins 0.000 description 1
• 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
• 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 206010040844 Skin exfoliation Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 229920002385 Sodium hyaluronate Polymers 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010057666 Transcription Factor CHOP Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• GZCGUPFRVQAUEE-ZXXMMSQZSA-N aldehydo-D-idose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-ZXXMMSQZSA-N 0.000 description 1
• PYMYPHUHKUWMLA-UOWFLXDJSA-N aldehydo-D-lyxose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-UOWFLXDJSA-N 0.000 description 1
• GZCGUPFRVQAUEE-KAZBKCHUSA-N aldehydo-D-talose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KAZBKCHUSA-N 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 230000037354 amino acid metabolism Effects 0.000 description 1
• 229940067621 aminobutyrate Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 239000011609 ammonium molybdate Substances 0.000 description 1
• APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
• 235000018660 ammonium molybdate Nutrition 0.000 description 1
• 229940010552 ammonium molybdate Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000002882 anti-plaque Effects 0.000 description 1
• 229940124604 anti-psychotic medication Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 230000005756 apoptotic signaling Effects 0.000 description 1
• 239000012223 aqueous fraction Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 230000008952 bacterial invasion Effects 0.000 description 1
• 230000007375 bacterial translocation Effects 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 101150024147 bax gene Proteins 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000004397 blinking Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 150000001669 calcium Chemical class 0.000 description 1
• 230000005880 cancer cell killing Effects 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 231100000260 carcinogenicity Toxicity 0.000 description 1
• 230000007670 carcinogenicity Effects 0.000 description 1
• 230000001925 catabolic effect Effects 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000001055 chewing effect Effects 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000007398 colorimetric assay Methods 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 229940021746 d- serine Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• 208000002925 dental caries Diseases 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000035618 desquamation Effects 0.000 description 1
• 238000001784 detoxification Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 235000018823 dietary intake Nutrition 0.000 description 1
• 238000001085 differential centrifugation Methods 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 229940120503 dihydroxyacetone Drugs 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000002828 effect on organs or tissue Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000002662 enteric coated tablet Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000008378 epithelial damage Effects 0.000 description 1
• 230000009841 epithelial lesion Effects 0.000 description 1
• 235000019414 erythritol Nutrition 0.000 description 1
• 229940009714 erythritol Drugs 0.000 description 1
• UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
• UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
• 125000003916 ethylene diamine group Chemical class 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000011790 ferrous sulphate Substances 0.000 description 1
• 235000003891 ferrous sulphate Nutrition 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000020375 flavoured syrup Nutrition 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 235000015203 fruit juice Nutrition 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
• 108010068906 gamma-glutamylcysteine Proteins 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 210000005095 gastrointestinal system Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000004110 gluconeogenesis Effects 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 229940045883 glutathione disulfide Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 125000005908 glyceryl ester group Chemical group 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229940043257 glycylglycine Drugs 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
• 150000002453 idose derivatives Chemical class 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 208000022760 infectious otitis media Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
• 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• 230000004317 lacrimation Effects 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000002502 lymphedema Diseases 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000004137 mechanical activation Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000007102 metabolic function Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229920003087 methylethyl cellulose Polymers 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 235000020166 milkshake Nutrition 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000006667 mitochondrial pathway Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• 230000000050 nutritive effect Effects 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 210000003300 oropharynx Anatomy 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 235000016236 parenteral nutrition Nutrition 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000004963 pathophysiological condition Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 229920001987 poloxamine Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000000700 radioactive tracer Substances 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 230000006950 reactive oxygen species formation Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229940043230 sarcosine Drugs 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 229960001153 serine Drugs 0.000 description 1
• 208000021160 simian immunodeficiency virus infection Diseases 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229940010747 sodium hyaluronate Drugs 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
• RMJPDRUNCDRUQC-MCDZGGTQSA-M sodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O RMJPDRUNCDRUQC-MCDZGGTQSA-M 0.000 description 1
• 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 230000036561 sun exposure Effects 0.000 description 1
• 239000010414 supernatant solution Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 229920001187 thermosetting polymer Polymers 0.000 description 1
• 239000004634 thermosetting polymer Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical group 0.000 description 1
• 230000009974 thixotropic effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 125000005591 trimellitate group Chemical group 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1
• RITKHVBHSGLULN-CRCLSJGQSA-N γ-glutamylcysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](CS)C(O)=O RITKHVBHSGLULN-CRCLSJGQSA-N 0.000 description 1